| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | BUY | BUY | SELL | NEUTRAL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 11.30▼ | 11.29▼ | 11.30▼ | 11.28▼ | 11.29▼ |
| MA10 | 11.30▼ | 11.28▼ | 11.27▼ | 11.30▼ | 11.28▼ |
| MA20 | 11.27▼ | 11.22▲ | 11.21▲ | 11.30▼ | 11.22▲ |
| MA50 | 11.11▲ | 11.02▲ | 11.00▲ | 11.27▼ | 10.97▲ |
| MA100 | 10.91▲ | 10.83▲ | 10.80▲ | 11.20▲ | N/A |
| MA200 | 10.66▲ | 10.58▲ | N/A | 11.01▲ | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.011▼ | -0.007▼ | -0.006▼ | -0.009▼ | -0.012▼ |
| RSI | 55.891▲ | 63.461▲ | 65.130▲ | 34.939▼ | 67.335▲ |
| STOCH | 72.222 | 78.638 | 79.167 | 15.320▼ | 64.790 |
| WILL %R | -100.000▼ | -57.143 | -50.000 | -100.000▼ | -55.556 |
| CCI | -93.333 | -10.428 | 6.289 | -176.952▼ | 14.153 |
|
Friday, June 13, 2025 07:07 AM
Keen Vision Acquisition Corporation does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization ...
|
|
Friday, June 13, 2025 06:17 AM
Medera is a clinical-stage biopharmaceutical company focused on targeting difficult-to-treat and currently incurable diseases by developing a range of next-generation therapeutics. Medera operates via ...
|
|
Thursday, June 12, 2025 05:00 PM
1 Day KVAC 0.00% DJIA 0.78% Russell 2K 0.89% Business/Consumer Services 2.89% ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 13/06/25 | 11.26 | 11.26 | 11.25 | 11.25 | 6,742 |
| 12/06/25 | 11.26 | 11.26 | 11.26 | 11.26 | 12 |
| 11/06/25 | 11.26 | 11.28 | 11.25 | 11.26 | 409 |
| 09/06/25 | 11.31 | 11.31 | 11.31 | 11.31 | 0 |
| 06/06/25 | 11.31 | 11.31 | 11.31 | 11.31 | 0 |
| 05/06/25 | 11.31 | 11.31 | 11.31 | 11.31 | 0 |
| 04/06/25 | 11.31 | 11.31 | 11.31 | 11.31 | 0 |
| 03/06/25 | 11.31 | 11.31 | 11.31 | 11.31 | 0 |
| 30/05/25 | 11.31 | 11.31 | 11.31 | 11.31 | 2 |
| 28/05/25 | 11.3299 | 11.3299 | 11.3299 | 11.3299 | 1,003 |
|
|
||||
|
|
||||
|
|